Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY-NC 4.0Journal of Hepatocellular Carcinoma

Targeting Ferroptosis-Mediated Tumor Microenvironment Remodeling in Hepatocellular Carcinoma: Therapeutic Resistance and Clinical Translation

4 affiliations
  1. 1Department of Pathology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang Province, 310023, People’s Republic of China
  2. 2Department of Clinical Pharmacy, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang Province, 311200, People’s Republic of China
  3. 3Department of Hepatology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang Province, 310023, People’s Republic of China
  4. 4Department of Pathology, Huzhou Central Hospital, Huzhou, Zhejiang Province, 313000, People’s Republic of China

Abstract

Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, largely because of marked etiological and molecular heterogeneity, an immunosuppressive tumor microenvironment (TME), high recurrence rates, and resistance to systemic and locoregional therapies. As the liver is central to iron handling, lipid metabolism, glutathione homeostasis, and oxidative stress regulation, ferroptosis has emerged as a biologically relevant vulnerability in HCC. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and restrained by antioxidant defense systems, including the SLC7A11–GSH–GPX4 axis, NRF2 signaling, and parallel ferroptosis-suppressive pathways. Because ferroptosis can promote tumor-cell elimination yet also drive hepatocyte injury, immune suppression, and stromal inflammation, its TME effects are bidirectional. This review asks which cellular compartments benefit or suffer from ferroptotic stress, how etiology and iron redistribution shape therapeutic responses, and how tumor-selective intervention can be translated safely in cirrhotic patients. This review provides a TME-centered synthesis of ferroptosis in HCC, emphasizing how ferroptotic signaling interacts with immune cells, stromal components, metabolic remodeling, angiogenesis, and inflammatory liver injury. We discuss the role of ferroptosis in resistance to targeted therapy, radiotherapy, transarterial therapy, and immunotherapy, and summarize emerging strategies involving natural compounds, chemical ferroptosis inducers, nanomedicine-based delivery systems, predictive biomarkers, and rational combination regimens. Finally, we highlight key translational challenges, including tumor-selective ferroptosis induction, protection of non-malignant liver tissue, biomarker validation, and safety evaluation in clinically relevant models. Understanding ferroptosis-mediated TME remodeling may provide new opportunities to overcome therapeutic resistance and improve outcomes for patients with HCC.

Related

  1. Ferroptosis in cancer: molecular mechanisms, tumour microenvironment, therapeutic resistance, and clinical translation.
    Ghisaram Dewasi, Sakshi Jain
    Journal of the Egyptian National Cancer InstitutePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Ferroptosis-related lncRNA signature predicts prognosis and immune microenvironment remodeling in laryngeal squamous cell carcinoma
    Haibo Xu, Meiling Xu, Huijie Weng +3
    Discover OncologyPeer-reviewedCC BYFull textOncologyDOAJ
  3. CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
    Ankit Kumar Bijaraniya, Tao Lide
    CureusPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Therapeutic potential of natural product polysaccharides in hepatocellular carcinoma: from microenvironment modulation to combination strategies
    Qingmiao Shi, Yile Liang, Yaping Zhang +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  5. Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation
    S. M. Nashir Udden, Monira Obaid, Laurentiu M. Pop +1
    International journal of molecular sciencesPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
BibTeX
@article{liu2026targeting,
  title = {{Targeting Ferroptosis-Mediated Tumor Microenvironment Remodeling in Hepatocellular Carcinoma: Therapeutic Resistance and Clinical Translation}},
  author = {Hong Liu and Xiaoying Zhang and Jianfeng Bao and Xiantu Zhang and Jing Gao and Jin Liu},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  month = nov,
  doi = {10.2147/jhc.s640515},
  url = {https://doi.org/10.2147/jhc.s640515},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Targeting Ferroptosis-Mediated Tumor Microenvironment Remodeling in Hepatocellular Carcinoma: Therapeutic Resistance and Clinical Translation
AU  - Hong Liu
AU  - Xiaoying Zhang
AU  - Jianfeng Bao
AU  - Xiantu Zhang
AU  - Jing Gao
AU  - Jin Liu
PY  - 2026
DA  - 2026/11/04
JO  - Journal of Hepatocellular Carcinoma
DO  - 10.2147/jhc.s640515
UR  - https://doi.org/10.2147/jhc.s640515
AB  - Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, largely because of marked etiological and molecular heterogeneity, an immunosuppressive tumor microenvironment (TME), high recurrence rates, and resistance to systemic and locoregional therapies. As the liver is central to iron handling, lipid metabolism, glutathione homeostasis, and oxidative stress regulation, ferroptosis has emerged as a biologically relevant vulnerability in HCC. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and restrained by antioxidant defense systems, including the SLC7A11–GSH–GPX4 axis, NRF2 signaling, and parallel ferroptosis-suppressive pathways. Because ferroptosis can promote tumor-cell elimination yet also drive hepatocyte injury, immune suppression, and stromal inflammation, its TME effects are bidirectional. This review asks which cellular compartments benefit or suffer from ferroptotic stress, how etiology and iron redistribution shape therapeutic responses, and how tumor-selective intervention can be translated safely in cirrhotic patients. This review provides a TME-centered synthesis of ferroptosis in HCC, emphasizing how ferroptotic signaling interacts with immune cells, stromal components, metabolic remodeling, angiogenesis, and inflammatory liver injury. We discuss the role of ferroptosis in resistance to targeted therapy, radiotherapy, transarterial therapy, and immunotherapy, and summarize emerging strategies involving natural compounds, chemical ferroptosis inducers, nanomedicine-based delivery systems, predictive biomarkers, and rational combination regimens. Finally, we highlight key translational challenges, including tumor-selective ferroptosis induction, protection of non-malignant liver tissue, biomarker validation, and safety evaluation in clinically relevant models. Understanding ferroptosis-mediated TME remodeling may provide new opportunities to overcome therapeutic resistance and improve outcomes for patients with HCC.
SN  - 2253-5969
ER  -